MAP Pharmaceuticals, Inc.

Form 4

October 12, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB

3235-0287 Number:

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person * Freund John Gordon

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Middle)

(Zin)

MAP Pharmaceuticals, Inc. [MAPP] 3. Date of Earliest Transaction

(Check all applicable)

C/O SKYLINE VENTURES, 125

(Month/Day/Year) 10/11/2007

X_ Director 10% Owner Officer (give title _ Other (specify

UNIVERSITY AVENUE, GARDEN **LEVEL**

(State)

(First)

(Street) 4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

PALO ALTO, CA 94301

(City)	(State)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities And Disposed of (Instr. 3, 4 and Amount	D)	ed (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/11/2007		J <u>(1)</u>	128,862	A	\$ 14.502	212,195	I	See footnote (2)
Common Stock	10/11/2007		С	1,638,797	A	\$ 14.502	1,850,992	I	See footnote (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	<u>(4)</u>	10/11/2007	10/11/2007	C	779,871	<u>(5)</u>	(5)	Common Stock	779,871
Series C Preferred Stock	<u>(4)</u>	10/11/2007	10/11/2007	C	320,690	<u>(5)</u>	<u>(5)</u>	Common Stock	320,690
Series D Preferred Stock	<u>(4)</u>	10/11/2007	10/11/2007	C	538,236	<u>(5)</u>	(5)	Common Stock	538,236

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			

Freund John Gordon C/O SKYLINE VENTURES 125 UNIVERSITY AVENUE, GARDEN LEVEL PALO ALTO, CA 94301

X

Deletionships

Signatures

/s/ John G. Freund,
M.D.

**Signature of Reporting

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Received pursuant to a cumulative stock dividend accumulated through September 14, 2007, at which time further accumulation ended, to holders of the issuer's preferred stock upon the closing of the issuer's initial public offiering.
- (2) Represents 102,644 shares held by Skyline Venture Partners Qualified Purchaser Fund III, L.P. ("SVPQFIII"), 23,730 shares held by Skyline Venture Partners III, L.P. ("SVPIII") and 85,821 shares held by Skyline Expansion Fund, L.P. ("SEF"). Skyline Venture Management III, LLC ("SVMIII) is the General Partner of both SVPQFIII and SVPIII, as well as the Managing Member of Skyline Expansion Fund Management, LLC, the General Partner of SEF. In such capacities, SVMIII may be deemed to share voting and

Reporting Owners 2

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

investment powers with respect to the shares of Common Stock held by SVPIII, SVPQFIII, and John Freund and Yasunori Kaneko as Managing Directors of SVMIII may be deemed to share voting and investment power with respect to the shares of Common Stock held by SVPIII and SVPQFIII. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Represents 1,625,070 shares held by SVPQFIII, 61,633 shares held SVPIII and 164,289 shares held by SEF. SVMIII is the General Partner of both SVPQFIII and SVPIII, as well as the Managing Member of Skyline Expansion Fund Management, LLC, the General

- (3) Partner of SEF. In such capacities, SVMIII may be deemed to share voting and investment powers with respect to the shares of Common Stock held by SVPIII, SVPQFIII, and John Freund and Yasunori Kaneko as Managing Directors of SVMIII may be deemed to share voting and investment power with respect to the shares of Common Stock held by SVPIII and SVPQFIII. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- (4) All outstanding shares of the issuer's preferred stock were automatically converted into common stock on a 1-for-1 basis upon the closing of the issuer's intial public offering, for no additional consideration.
- (5) Not applicable, see Note 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.